155 related articles for article (PubMed ID: 37792268)
21. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
22. Integrative in silico and in vitro transcriptomics analysis revealed new lncRNAs related to intrinsic apoptotic genes in colorectal cancer.
Akbari F; Peymani M; Salehzadeh A; Ghaedi K
Cancer Cell Int; 2020 Nov; 20(1):546. PubMed ID: 33292233
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
Conti A; Majorini MT; Elliott R; Ashworth A; Lord CJ; Cancelliere C; Bardelli A; Seneci P; Walczak H; Delia D; Lecis D
Oncotarget; 2015 May; 6(13):10994-1008. PubMed ID: 26028667
[TBL] [Abstract][Full Text] [Related]
24. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
25. Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells.
Saliani M; Jalal R; Javadmanesh A
Sci Rep; 2022 May; 12(1):7965. PubMed ID: 35562390
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m
Zhou L; Jiang J; Huang Z; Jin P; Peng L; Luo M; Zhang Z; Chen Y; Xie N; Gao W; Nice EC; Li JQ; Chen HN; Huang C
Mol Cancer; 2022 Aug; 21(1):168. PubMed ID: 35986274
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway.
Yu J; Han Z; Sun Z; Wang Y; Zheng M; Song C
J Exp Clin Cancer Res; 2018 Sep; 37(1):222. PubMed ID: 30201010
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.
Li Y; Huang S; Li Y; Zhang W; He K; Zhao M; Lin H; Li D; Zhang H; Zheng Z; Huang C
Tumour Biol; 2016 Oct; 37(10):14205-14215. PubMed ID: 27553025
[TBL] [Abstract][Full Text] [Related]
29. LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway.
Zhang T; Yu S; Zhao S
Adv Clin Exp Med; 2021 Aug; 30(8):839-848. PubMed ID: 34286520
[TBL] [Abstract][Full Text] [Related]
30. The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2.
Wang H; Wu Y; Wang Z; Chen Y; Mo J; Guan W; Zhang Y; Yao H
Oncol Res; 2021; 29(3):201-215. PubMed ID: 37304670
[TBL] [Abstract][Full Text] [Related]
31. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
[TBL] [Abstract][Full Text] [Related]
32. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
[No Abstract] [Full Text] [Related]
33. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of lncRNAs SNHG6, TRPM2-AS1, MIR4435-2HG, and hypomethylation of TRPM2-AS1 promoter in colorectal cancer.
Ghasemi T; Khalaj-Kondori M; Hosseinpour Feizi MA; Asadi P
Cell Biol Int; 2021 Dec; 45(12):2464-2478. PubMed ID: 34431156
[TBL] [Abstract][Full Text] [Related]
35. LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS.
Chen Q; Zhou L; Ma D; Hou J; Lin Y; Wu J; Tao M
J Transl Med; 2022 Aug; 20(1):356. PubMed ID: 35962353
[TBL] [Abstract][Full Text] [Related]
36. Circulating miRNAs and lncRNAs serve as biomarkers for early colorectal cancer diagnosis.
Lotfi E; Kholghi A; Golab F; Mohammadi A; Barati M
Pathol Res Pract; 2024 Mar; 255():155187. PubMed ID: 38377721
[TBL] [Abstract][Full Text] [Related]
37. lncRNA ZNF667-AS1 (NR_036521.1) inhibits the progression of colorectal cancer via regulating ANK2/JAK2 expression.
Zhuang L; Ding W; Ding W; Zhang Q; Xu X; Xi D
J Cell Physiol; 2021 Mar; 236(3):2178-2193. PubMed ID: 32853419
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
39. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
Li X; Deng SJ; Zhu S; Jin Y; Cui SP; Chen JY; Xiang C; Li QY; He C; Zhao SF; Chen HY; Niu Y; Liu Y; Deng SC; Wang CY; Zhao G
Oncotarget; 2016 Feb; 7(5):6000-14. PubMed ID: 26755660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
